No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PEN240517P240000
- 21.80
- 0.000.00%
15min DelayTrading Mar 22 09:48 ET
0.00High0.00Low
0.00Open21.80Pre Close0 Volume0 Open Interest240.00Strike Price0.00Turnover0.00%IV-0.09%PremiumMay 17, 2024Expiry Date33.56Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma6.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Penumbra, Inc. (NYSE:PEN) Q1 2024 Earnings Call Transcript
Penumbra Price Target Cut to $272.00/Share From $284.00 by Canaccord Genuity
Penumbra Price Target Cut to $272.00/Share From $284.00 by Canaccord Genuity
Penumbra Is Maintained at Buy by Canaccord Genuity
Penumbra Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Penumbra, Lowers Price Target to $272
Canaccord Genuity analyst Jason Mills maintains Penumbra with a Buy and lowers the price target from $284 to $272.
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Price Target Cut to $260.00/Share From $290.00 by Piper Sandler
Penumbra Price Target Cut to $260.00/Share From $290.00 by Piper Sandler
Comments
Despite the high P/S ratio, shareholders are holding onto Penumbra's stocks due to its strong future revenue prospects. The strong revenue forecasts are expected to keep the share price buoyant unless the analysts have significantly misjudged the company's potential.
Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led Wall Street to spell doom for companies that have profited from obesity problem. However, the reaction on Wall Street has been extreme, creating opportunities for cooler heads, some analysts and investors say.
To be sure, drugs such as $Novo-Nordisk A/S(NVO.US$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
To be sure, drugs such as $Novo-Nordisk A/S(NVO.US$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
10
Penumbra's earnings outlook could be brighter than reflected in the statutory profit due to one-off items. The company's profitability this year shows a good sign after previous losses.
Penumbra's low ROE and declining net income over five years hint at sub-par performance. The earnings' decline, despite profit retention, could imply a struggling business or high payout ratio. Analyst estimates, however, foresee a better earnings growth rate.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Vertiv Holdings(VRT.US$ - up 18.6%
2. $Erie Indemnity(ERIE.US$ - up 8.7%
3. $Aspen Technology(AZPN.US$ - up 6.5%
4. $Penske Automotive(PAG.US$ - up 5.1%
5. $Humana(HUM.US$ - up 3.7%
6. $Teva Pharmaceutical Industries(TEVA.US$ - up 3.7%
7. $Encompass Health(EHC.US$ - up 3.0%
8. $Emerson Electric(EMR.US$ - up 2.8...
Gap Ups
1. $Vertiv Holdings(VRT.US$ - up 18.6%
2. $Erie Indemnity(ERIE.US$ - up 8.7%
3. $Aspen Technology(AZPN.US$ - up 6.5%
4. $Penske Automotive(PAG.US$ - up 5.1%
5. $Humana(HUM.US$ - up 3.7%
6. $Teva Pharmaceutical Industries(TEVA.US$ - up 3.7%
7. $Encompass Health(EHC.US$ - up 3.0%
8. $Emerson Electric(EMR.US$ - up 2.8...
+16
11
Read more